Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board

Annette Hasenburg Prof., Dr, med Advisory Board

David Henry MD Advisory Board

See All Experts

Published in Oncology

Journal Scan / Research · September 24, 2022

Higher Transferrin Saturation Predicts Inferior Clinical Outcomes in Patients With MDS

Haematologica

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Charles Gaulin MBBS

Haematologica

High transferrin saturation predicts inferior clinical outcomes in patients with MDS

Haematologica 2022 Aug 18;[EPub Ahead of Print], J Teichman, M Geddes, N Zhu, MM Keating, M Sabloff, G Christou, B Leber, D Khalaf, E St-Hilaire, N Finn, A Shamy, KWL Yee, JM Storring, TJ Nevill, R Delage, M Elemary, V Banerji, B Houston, L Mozessohn, L Chodirker, L Zhang, M Siddiqui, A Parmentier, HA Leitch, RJ Buckstein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Higher Transferrin Saturation Predicts Inferior Clinical Outcomes in Patients With MDS

Additional Info

High transferrin saturation predicts inferior clinical outcomes in patients with MDS

Further Reading

Final Note From the Oncology Editors

Invasive Disease–Free Survival Outcomes With SLNB vs Omission of Axillary Surgery in Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Surgery

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

Genomic Instability in Non–Breast or Ovarian Malignancies Among Individuals With Germline Pathogenic Variants in BRCA1/2

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Obecabtagene Autoleucel for Adults With B-Cell Acute Lymphoblastic Leukemia

De-Escalated Neoadjuvant Weekly Nab-Paclitaxel With Trastuzumab and Pertuzumab vs Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab for HER2-Positive Early Breast Cancer

Blinatumomab in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia

Tremelimumab and Durvalumab as Neoadjuvant or Non-Operative Management Strategy for Microsatellite Instability–High Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Efficacy and Safety of Prostate Radiotherapy in Patients With De Novo Metastatic Castration-Sensitive Prostate Cancer

Recently Updated